2026-01-23 - Analysis Report
**Company Overview**
Merck is a global healthcare company that discovers, develops, and manufactures pharmaceuticals and vaccines.

**Return Rate Comparison**

* Ticker to review: MRK
* Company Name: Merck
* Cumulative return of review stock: 26.08%
* Cumulative return of comparison stock (S&P 500, VOO): 92.53%
* Divergence: -67.60 (max: 25.90, min: -97.40, relative divergence: 24.20%)

The return rate of Merck (MRK) is lower than the S&P 500 (VOO) by 66.45%. 

**Alpha and Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 24.0% | 14.7% | 20.0% | 0.7  | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 19.0% | 0.7  | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7  | 195.0B |
| 2019-2021  | 0.0%  | 19.3% | -43.0% | 0.6  | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5  | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3  | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3  | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3  | 262.9B |

**Recent Stock Price Fluctuations**

* Close: $109.18
* Last-market: {'price': 109.18, 'previousClose': 111.11, 'change': -1.74}
* 5-day SMA: $109.91
* 20-day SMA: $108.35
* 60-day SMA: $99.57

**RSI, PPO Index, and Delta_Previous_Relative_Divergence Analysis**

* Market Risk Indicator (MRI): 0.90
* RSI: 60.80
* PPO: -0.32
* Recent (20 days) relative divergence change: -1.00
* 7-day Rank change: 35
* 7-day Dynamic Expected Return change: -2.90
* Expected Return (%): -29.60%

**Recent News & Significant Events (Yahoo Finance)**

[2026-01-22] Merck Stock Shares $91 Bil Success With Investors - Trefis
[2026-01-22] ABBV vs. MRK: An Oncology-Immunology Showdown for Investors - The Globe and Mail
[2026-01-15] Is Merck Stock A Trap At $110? - Forbes
[2026-01-22] Assessing Merck (MRK) Valuation As Recent Gains Put Focus On Earnings And Cash Flow Potential - simplywall.st
[2026-01-21] Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.5% on Analyst Upgrade - MarketBeat
[2026-01-21] Assessing Merck (MRK) Valuation After Recent Share Price Momentum And DCF Discount Signals - Yahoo Finance

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 115.11 / 135.00 / 83.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-11-05 | 2.32 | $17.28B |
| 2025-08-05 | 1.76 | $15.81B |
| 2025-05-02 | 2.01 | $15.53B |
| 2024-11-06 | 1.25 | $16.66B |
| 2025-11-05 | 1.25 | $16.66B |

**Financial Information - Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Financial Information - Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis (Summary of previous items)**

The return rate of Merck (MRK) is lower than the S&P 500 (VOO) by 66.45%.
The stock price has been fluctuating, with a recent sharp decline.
The Market Risk Indicator (MRI) is 0.90, indicating a high-risk investment.
The Analyst Consensus is Buy, with a mean rating of 1.90 and a target price of $115.11.
The recent earnings analysis shows improving revenue and EPS.
The financial information indicates stable revenue and profit margins, with a ROE of 11.16%.
Considering these factors, the overall analysis suggests a cautious approach to investing in Merck (MRK).

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.